Cancer Cell Patents (Class 424/155.1)
-
Patent number: 12227574Abstract: The present application provides tumor microenvironment acidity activated anti-CD3 constructs that bind to CD3 (e.g., anti-CD3 monoclonal and multispecific antibodies), nucleic acid molecules encoding an amino acid sequence of the anti-CD3, vectors comprising the nucleic acid molecules, host cells containing the vectors, methods of preparing the anti-CD3 construct, pharmaceutical compositions containing the anti-CD3 construct, and methods of using the anti-CD3 construct or compositions.Type: GrantFiled: June 16, 2022Date of Patent: February 18, 2025Assignee: AMBERSTONE BIOSCIENCES, INC.Inventors: Yonglei Shang, Aude I. Segaliny, Xiaoya Ma, Xianzhi Jiang, George Wu
-
Patent number: 12214035Abstract: The present disclosure relates to liquid and dried compositions comprising a live, attenuated or genetically modified herpesvirus and methods of preparing such compositions, in one aspect, the composition comprises at least two or more pharmaceutically acceptable excepients, at least one of which is histidine and at least one of which is a sugar or sugar alcohol. The compostions retain a sufficiently high infectious titre following storage or large-scale manufacturing steps, such as lyophilization.Type: GrantFiled: January 14, 2022Date of Patent: February 4, 2025Assignees: SANOFI PASTEUR LIMITED, SANOFI PASTEUR INC.Inventors: Stephen Anderson, Simon Delagrave, John Hamberger, Qinglian Li, Sophia Mundle, Nausheen Rahman
-
Patent number: 12213962Abstract: The present disclosure is generally related to methods for combining chemotherapy and immunotherapy for the treatment of a cancer.Type: GrantFiled: December 9, 2019Date of Patent: February 4, 2025Assignees: Emory University, The UAB Research Foundation, Children's Healthcare of Atlanta, Inc.Inventors: Harold Trent Spencer, Anindya Dasgupta, Lawrence S. Lamb
-
Patent number: 12195551Abstract: The invention relates to methods of treating of subject that has breast cancer or is at risk of having said cancer, comprising administering to the subject in need thereof a combination of a therapeutically effective amount of an ErbB-2/ErbB-3 bispecific antibody and a therapeutically effective amount of an endocrine therapy drug, wherein the bispecific antibody has an antigen binding site that can bind an extra-cellular part of ErbB-2 and an antigen binding site that can bind an extra-cellular part of ErbB-3; and to means for said method.Type: GrantFiled: May 17, 2018Date of Patent: January 14, 2025Assignee: Merus N.V.Inventors: David Andre Baptiste Maussang-Detaille, Cecilia Anna Wilhelmina Geuijen
-
Patent number: 12158424Abstract: Described herein are novel rapid and reliable methods of detection of extracellular vesicles and quantifying extracellular vesicle concentrations and absolute number from various sources, including raw cell harvest. The methods described herein comprise detection of intrinsic fluorescence of extracellular vesicles in biological samples. Extracellular vesicles analyzed by the methods of this application have a stereotypical elution profile distinct from known contaminants. The methods described herein are a significant improvement over the state of the art and fulfills an unmet need in the field of extracellular vesicle manufacturing and quality control.Type: GrantFiled: March 28, 2022Date of Patent: December 3, 2024Assignee: LONZA SALES AGInventors: Damian J. Houde, Young Jun Choi, John D. Kulman, Douglas E. Williams
-
Patent number: 12158400Abstract: The present invention contemplates use of encapsulated aqueous and non-aqueous reagents, solutions and solvents and their use in laboratory procedures. These encapsulated aqueous or non-aqueous reagents, solutions and solvents can be completely contained or encapsulated in microcapsules or nanocapsules that can be added to an aqueous or non-aqueous carrier solution or liquid required for medical and research laboratory testing of biological or non-biological specimens.Type: GrantFiled: August 26, 2022Date of Patent: December 3, 2024Inventor: Lee H. Angros
-
Patent number: 12116406Abstract: Anti-CD33 antibodies are described. The anti-CD33 antibodies can bind within the V-set Ig-like domain or the C2-set Ig-like domain of CD33. Epitopes FIG. 1A on the C2-set Ig-like domain can provide a “pan-binding” site, to which the cognate antibody will bind regardless of whether the CD33 molecule also contains the V-set domain (as in, for example, CD33FL) or not (as in, for example, CD33?E2). Alternative epitopes on the C2-set Ig-like domain are accessible for binding if the V-set domain is absent (e.g., as in CD33?E2). Antibodies that bind an epitope on the C2-set Ig-like domain (whether they exhibit pan or V-set absent binding) are directed at novel therapeutic targets can increase therapeutic efficacy against CD-33-related disorders. Also described are molecules comprising a binding-competent domain from at least one described anti-CD33 antibody, including scFvs, bi-specific antibody molecules, chimeric antigen receptors, and immunoconjugates. Methods of use are also provided.Type: GrantFiled: May 25, 2018Date of Patent: October 15, 2024Assignee: Fred Hutchinson Cancer CenterInventors: Roland B. Walter, Christopher Mehlin, George S. Laszlo, Colin E. Correnti
-
Patent number: 12071480Abstract: Humanized antibodies, including masked antibodies that specifically bind to CD47 are provided. Methods for using anti-CD47 antibodies, including masked antibodies, to modulate activity of (e.g., inhibit proliferation of) a CD47-expressing cell, as well as for the treatment of one or more diseases or disorders (e.g., cancer) associated with CD47-expressing cells, are provided.Type: GrantFiled: October 20, 2021Date of Patent: August 27, 2024Assignee: Seagen Inc.Inventors: Shyra Gardai, Matthew Levengood, Vivian Trang, Lori Westendorf, Christopher Carosino, Che Leung-Law, Michael Feldhaus
-
Patent number: 12049495Abstract: The present invention provides anti-VEGF antibodies formulated as high concentration, aqueous pharmaceutical compositions, suitable for an injection, preferably an intravitreal injection. The aqueous pharmaceutical compositions are useful for delivery of a high concentration of the antibody active ingredient to a patient without high levels of antibody aggregation and without a high level of sub-visible particulate matter. An aqueous composition of the invention comprises an antibody having a concentration of at least 50 mg/ml. An aqueous pharmaceutical composition of the invention includes a sugar, a buffering agent, and a surfactant.Type: GrantFiled: May 11, 2020Date of Patent: July 30, 2024Assignee: NOVARTIS AGInventors: Huixiang Zhang, Charles Boring, Alok Kulshreshtha, Yuhong Zeng, Li Wan, Laman Alani
-
Patent number: 12018071Abstract: Provided herein are single-chain chimeric polypeptides that include: (i) a first target-binding domain; (ii) a soluble tissue factor domain; and (iii) a second target-binding domain. Also provided here are methods of using these single-chain chimeric polypeptides and nucleic acids encoding these single-chain chimeric polypeptides.Type: GrantFiled: July 22, 2022Date of Patent: June 25, 2024Assignee: HCW Biologics, Inc.Inventor: Hing Wong
-
Patent number: 11987619Abstract: Provided herein are single-chain chimeric polypeptides that include: (i) a first target-binding domain; (ii) a soluble tissue factor domain; and (iii) a second target-binding domain. Also provided here are methods of using these single-chain chimeric polypeptides and nucleic acids encoding these single-chain chimeric polypeptides.Type: GrantFiled: July 21, 2022Date of Patent: May 21, 2024Assignee: HCW Biologics, Inc.Inventor: Hing Wong
-
Patent number: 11970546Abstract: The present disclosure provides antibodies specific for Mucin 1. Nucleic acids that encode one or both of the variable chains of an antibody of the present disclosure are also provided, as are cells that include such nucleic acids. Also provided are compositions that include the antibodies of the present disclosure, including in some instances, pharmaceutical compositions. Methods of making and using the antibodies of the present disclosure are also provided. In certain aspects, provided are methods that include administering to an individual having a cell proliferative disorder a therapeutically effective amount of an antibody of the present disclosure, where the antibody is administered to the individual to enhance an immune response, e.g., a T cell response, to abnormally proliferating cells of the cell proliferative disorder. The antibodies are also useful in various diagnostic, and monitoring applications, which are also provided.Type: GrantFiled: July 30, 2021Date of Patent: April 30, 2024Assignee: R.P. SCHERER TECHNOLOGIES, LLCInventors: David Rabuka, Penelope M. Drake, Yun Cheol Kim, Robyn M. Barfield, Maxine Bauzon, Ayodele Ogunkoya
-
Patent number: 11918770Abstract: Provided herein is an implant for delivering a hydrophobic active agent to a target tissue. The implant may include a scaffold defining a first surface and a second surface opposite the first surface, wherein the scaffold is substantially impermeable to a hydrophobic active agent, and a silicone tubing having a wall permeable to the active agent, wherein a first length of the silicone tubing is affixed to the first surface of the scaffold, wherein the two ends of the silicone tubing extend from the first surface, and wherein a path outlined by a second length of the tubing within the first length is circuitous. Also provided is a method of using the implant to locally deliver a hydrophobic active agent to a target tissue, and kits that find use in performing the present method.Type: GrantFiled: February 7, 2022Date of Patent: March 5, 2024Assignee: The Regents of the University of CaliforniaInventors: Pamela Munster, Jim Kiriakis, Hani Sbitany, Scott Thomas
-
Patent number: 11920156Abstract: The present invention provides engineered Natural Killer (NK) cells and methods of producing engineered NK cells. The engineered NK cells and compositions containing the engineered NK cells are useful for treating diseases such as cancer.Type: GrantFiled: February 8, 2018Date of Patent: March 5, 2024Assignee: Indapta Therapeutics, Inc.Inventor: Guy Dipierro
-
Patent number: 11814686Abstract: The present invention relates to the diagnostic of cancerous subject. Indeed, the inventors observed by using a Q-PCR based methods and sequencing methods that quantification of specific single stranded DNA fragments obtained from cell free nucleic acids (cfDNA) may discriminate cfDNA from healthy and cancer derived subjects. Single stranded DNA fragments obtained from CfDNA or specific range of single stranded DNA fragments are rather lower or higher when derived from healthy subject than from cancer subject. More, specific ratios for different size or range of single stranded DNA fragments varies between cancer subjects and healthy individuals. These values are sufficiently and significantly different to be used as values to determine whether a human subject may have cancer or not as a screening test.Type: GrantFiled: December 6, 2018Date of Patent: November 14, 2023Assignees: INSTITUT NATIONAL DE LA SANTÉDE LA RECHERCHE MÉDICALE, UNIVERSITÉ de MONTPELLIER, INSTITUT RéGIONAL DU CANCER DE MONTPELLIERInventors: Alain Thierry, Cynthia Sanchez
-
Patent number: 11773180Abstract: An object of the present invention is to provide a bispecific antibody comprising an antigen-binding domain that binds to CD40 and an antigen-binding domain that binds to an epithelial cell adhesion molecule (EpCAM). The present invention relates to a bispecific antibody comprising an antigen-binding domain that binds to CD40 and an antigen-binding domain that binds to EpCAM.Type: GrantFiled: November 6, 2018Date of Patent: October 3, 2023Assignee: KYOWA KIRIN CO., LTD.Inventors: Makoto Nakayama, Nobuaki Takahashi, Sayaka Maeda, Rinpei Niwa
-
Patent number: 11746355Abstract: The present invention relates to pathogen-resistant plants. In one aspect, plants comprising a heterologous expression cassette are provided, wherein the expression cassette comprises a polynucleotide that inhibits expression of a fungal pathogen gene and wherein the plant has increased resistance to a fungal pathogen or multiple pathogens compared to a control plant lacking the expression cassette. In another aspect, contacting a plant or a plant part with double stranded RNAs or small RNAs that inhibit expression of a fungal target gene or genes from multiple pathogens, wherein the plant has increased resistance to a pathogen or multiple pathogens compared to control plants that has not been contacted with the RNAs. Methods of making and cultivating pathogen-resistant plants are also provided.Type: GrantFiled: October 4, 2018Date of Patent: September 5, 2023Assignee: The Regents of The University of CaliforniaInventor: Hailing Jin
-
Patent number: 11721021Abstract: A method of detecting the presence of a prostate cancer in a human subject comprising the steps of (a) obtaining a histologically normal prostate tissue sample from the patient and (b) quantifying the epithelial thickness or gland lumen roundness of the tissue, wherein an increase in epithelial thickness or a decrease in gland lumen roundness indicates the presence of prostate cancer or a prostate cancer field defect.Type: GrantFiled: August 25, 2022Date of Patent: August 8, 2023Assignees: Wisconsin Alumni Research Foundation, The Medical College of Wisconsin, Inc.Inventors: David Frazier Jarrard, Bing Yang, Peter LaViolette
-
Patent number: 11672859Abstract: The present application provides a recombinant fusion protein containing an anti-PD-L1 antibody or an antibody fragment thereof, with each paratope of the anti-PD-L1 antibody or antibody fragment thereof linked via a linker to an extracellular Ig-like domain of a signal-regulatory protein (SIRP) at N-terminus of a heavy chain variable region or a light chain variable region constituting the paratope, wherein the recombinant fusion protein can bind to CD47, PD-L1 and FcR simultaneously. The present application also provides a nucleic acid molecule encoding the recombinant fusion protein, an expression vector containing the nucleic acid molecule, a method for producing the recombinant fusion protein and a method for treating a disease associated with over-expression of CD47 and/or PD-L1 using the recombinant fusion protein.Type: GrantFiled: October 7, 2021Date of Patent: June 13, 2023Assignee: IMMUNEONCO BIOPHARMACEUTICALS (SHANGHAI) INC.Inventors: Wenzhi Tian, Song Li
-
Patent number: 11654105Abstract: Fixed dose HER2 antibody formulations for subcutaneous administration are provided along with their use in the treatment of cancer. The formulations include fixed dose subcutaneous formulations of pertuzumab and subcutaneous co-formulations of pertuzumab and trastuzumab, and their use in the treatment of cancer.Type: GrantFiled: August 22, 2022Date of Patent: May 23, 2023Assignees: Genentech, Inc., Hoffmann-La RocheInventors: Jennifer Eng-Wong, Whitney Kirschbrown, Tarik Ali Khan, Jasper Lin, Sreedhara Alavattam, Amit Garg, Sarah Heeson, Tanja Badovinac-Crnjevic, Christine Wurth
-
Patent number: 11603410Abstract: Provided herein are methods of treating cancer using agonistic antibodies that specifically bind to immunostimulatory receptors, wherein the antibodies are administered in an amount and/or frequency sufficient to achieve and/or maintain a receptor occupancy of less than about 80%, for example, a receptor occupancy of about 20% to about 80%. Also provided are methods of determining human doses for such agonistic antibodies, and methods for monitoring receptor occupancy of the agonistic antibodies in order to maintain effective antibody levels in, e.g., human patients. Also provided are methods of measuring soluble OX40 in a subject. Also provided are methods of treating cancer, comprising administering to the subject an effective amount of each of an anti-OX40 antibody and an anti-PD-1 antibody.Type: GrantFiled: November 1, 2018Date of Patent: March 14, 2023Assignee: BRISTOL-MYERS SQUIBB COMPANYInventors: Marie-Claude Gaudreau, Chan Gao, Michael Quigley, Praveen Aanur
-
Patent number: 11591391Abstract: The present invention relates to the field of the production, identification and selection of biological binding molecules such as antibodies or fragments thereof, as well as to their use in the therapy and prophylaxis of cancer diseases, such as, in particular, malignant B-cell neoplasia. The binding molecules are able to selectively bind to autonomously active or autonomously activated B-cell receptors, the autonomously active or autonomously activated B-cell receptors being characterized by the presence of structural domains to which the binding molecule selectively binds and which are responsible for the autonomously active or autonomously activated state of the B-cell receptors.Type: GrantFiled: July 5, 2018Date of Patent: February 28, 2023Assignee: AVA Lifescience GmbHInventors: Ulrich Birsner, Hassan Jumaa, Holger Klapproth, Marc A. Kessemeier
-
Patent number: 11576912Abstract: Methods are provided for treating a subject having a MYC-driven neoplasia. Aspects of the methods include administering to the subject an amount of an inhibitor of a target gene effective to treat the subject for the MYC-driven neoplasia. Methods are also provided for identifying a MYC-dependent target gene in a MYC-driven neoplasia. Aspects of the method include identifying the MYC-dependent target gene based on a phenotype detected in a first tumor cell line conditionally expressing MYC that is absent or quantitatively different in a second tumor cell line conditionally repressing MYC when the two cell lines are contacted with a CRISPR-based gene silencing agent. Kits and cell lines for practicing the methods of the disclosure are also provided.Type: GrantFiled: January 3, 2018Date of Patent: February 14, 2023Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Anja Deutzmann, Dean W. Felsher, Yulin Li
-
Patent number: 11572413Abstract: The present invention provides for purified or highly pure recombinant monoclonal antibodies that bind to human colorectal and pancreatic carcinoma-associated antigens (CPAA), along with nucleic acid sequences encoding the antibody chains, and the amino acid sequences corresponding to said nucleic acids and uses for said sequences.Type: GrantFiled: June 12, 2019Date of Patent: February 7, 2023Assignee: PRECISION BIOLOGICS, INC.Inventors: Myron Arlen, J. Andrew Bristol, Ariel Hollinshead, Kwong Tsang
-
Patent number: 11571459Abstract: Disclosed are surprising new methods and kits for treating patients, particularly cancer patients, using bavituximab in combination therapies with immuno-oncology (IO) agents such as checkpoint inhibitor antibodies. The methods and kits are based on the surprising finding that human patients treated with bavituximab and checkpoint inhibitor antibodies have a statistically significant prolonged survival in controlled studies.Type: GrantFiled: April 2, 2018Date of Patent: February 7, 2023Assignee: ONCXERNA THERAPEUTICS, INC.Inventors: Joseph S. Shan, Nikoletta L. Kallinteris, Min Tang, F. Andrew Dorr
-
Patent number: 11530274Abstract: The disclosure provides novel antigen-binding proteins that bind STEAP1 and methods of use.Type: GrantFiled: July 2, 2019Date of Patent: December 20, 2022Assignees: AMGEN INC., XENCOR, INC.Inventors: Olivier Nolan-Stevaux, Cong Li, Christopher M. Murawsky, Benjamin M. Alba, Neeraj Jagdish Agrawal, Kevin Graham, Jennitte LeAnn Stevens, Gregory Moore
-
Patent number: 11518802Abstract: The invention relates to monoclonal antibodies, in particular against a peptide of the BAMBI protein, as well as the uses thereof and methods comprising same. Preferably, the antibodies are used for the treatment of autoimmune diseases.Type: GrantFiled: November 30, 2016Date of Patent: December 6, 2022Assignees: CONSEJO SUPERIOR DE INVESTIGACIONES CIENTIFICAS (CSIC), UNIVERSIDAD DE CANTABRIAInventors: Jesús Merino Pérez, Ramón Merino Pérez
-
Patent number: 11459378Abstract: In certain embodiments, described herein is a method of treating a subject infected with a pathogen encoding an Fc-binding protein comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an Fc region of an immunoglobulin G antibody. Also described herein is a method for treating cancer in a subject undergoing oncolytic viral therapy comprising administering to the subject a therapeutically effective amount of a pharmaceutical composition comprising an Fc region of an immunoglobulin G antibody. Further described herein is a method of activating natural killer (NK) cells in a subject infected with a pathogen, comprising administering to the subject a pharmaceutical composition comprising an Fc region of an immunoglobulin G antibody.Type: GrantFiled: January 30, 2018Date of Patent: October 4, 2022Assignee: OHIO STATE INNOVATION FOUNDATIONInventors: Michael Caligiuri, Jianhua Yu, Hongsheng Dai
-
Patent number: 11446378Abstract: Disclosed herein are compositions and methods for tumor treatment involving administering to a subject having a tumor with an amount effective to limit tumor growth or metastasis of an ephrin B1 inhibitor, or a pharmaceutically acceptable salt thereof; and/or an inhibitor of tumor exosomal release, or a pharmaceutically acceptable salt thereof.Type: GrantFiled: February 23, 2018Date of Patent: September 20, 2022Assignee: Sanford HealthInventor: Paola Vermeer
-
Patent number: 11434288Abstract: The present invention provides for diagnostic kits for identifying cancer patients who are more susceptible to cancer therapies employing endostatin and other angiogenesis inhibitors, based upon the discovery that Nucleolin is a specific receptor for Endostatin. In particular, the diagnostic kits include antibody molecules against Nucleolin, DNA or RNA molecules that specifically bind to nucleic acid molecules encoding Nucleolin. The present invention also discloses methods of screening for angiogenesis inhibitors which specifically interact with Nucleolin, and act as angiogenesis inhibitors in an analogous manner as Endostatin. In addition, the present invention discloses methods of inhibiting the proliferation of endothelial cells or angiogenesis of tumor by administering an anti-nucleolin antibody linked to a cytotoxic agent such as tumor necrosis factor alpha to the endothelial cells.Type: GrantFiled: March 26, 2009Date of Patent: September 6, 2022Assignees: Protogen Ltd., Tsinghua UniversityInventors: Yongzhang Luo, Hubing Shi
-
Patent number: 11401324Abstract: Provided herein are single-chain chimeric polypeptides that include: (i) a first target-binding domain; (ii) a soluble tissue factor domain; and (iii) a second target-binding domain. Also provided here are methods of using these single-chain chimeric polypeptides and nucleic acids encoding these single-chain chimeric polypeptides.Type: GrantFiled: August 29, 2019Date of Patent: August 2, 2022Assignee: HCW Biologics, Inc.Inventor: Hing Wong
-
Patent number: 11312749Abstract: The present invention relates to a heterotandem bicyclic peptide complex which comprises a first peptide ligand, which binds to EphA2, conjugated via a linker to two second peptide ligands, which bind to CD137. The invention also relates to the use of said heterotandem bicyclic peptide complex in preventing, suppressing or treating cancer.Type: GrantFiled: July 29, 2020Date of Patent: April 26, 2022Assignee: BicycleTx LimitedInventors: Gemma Mudd, Punit Upadhyaya, Kevin McDonnell, Johanna Lahdenranta
-
Patent number: 11248059Abstract: The present invention replaces an amino acid residue of a specific region of a parent antibody so as to improve the stability of the antibody, thereby improving druggability. A variant antibody of the present invention, compared to a parent antibody hz1E11, has significantly improved stability while having nearly the same productivity and efficacy. Therefore, the variant antibody of the present invention exhibits, in the development of HER2-specific antibodies, excellent characteristics such as reduction in production costs, inhibition of efficacy reduction and reduction of side effects.Type: GrantFiled: April 12, 2017Date of Patent: February 15, 2022Assignee: ABCLON INC.Inventors: Jong Seo Lee, Kyu Tae Kim, Young Ha Lee, In Sik Hwang, Bong Kook Ko
-
Patent number: 11230609Abstract: The present invention provides antibody polypeptides with binding specificity for human kallikrein-2 (hK2), wherein the antibody polypeptide comprises (a) a heavy chain variable region comprising the amino acid sequences of SEQ ID NO:1 and SEQ ID NO:2 and SEQ ID NO:3 and/or (b) a light chain variable region comprising the amino acid sequences of SEQ ID NO:4 and SEQ ID NO:5 and SEQ ID NO:6, and wherein the heavy chain variable region and light chain variable region comprise framework amino acid sequences from one or more human antibodies. The invention further provides use of said antibody polypeptides in the diagnosis and treatment of prostate cancer.Type: GrantFiled: August 30, 2018Date of Patent: January 25, 2022Assignee: Janssen Biotech, Inc.Inventors: Par Oskar Vilhelmsson Timmermand, Amanda Thuy Tran, Sven-Erik Strand, Urpo Juhani Lamminmaki, Kjell Sjostrom
-
Patent number: 11155617Abstract: Provided are a LAG-3 antibody, an antigen-binding fragment thereof, and a pharmaceutical application thereof. Further, provided are a chimeric antibody comprising a CDR of the LAG-3 antibody, a humanized antibody, a pharmaceutical composition comprising the LAG-3 antibody and the antigen-binding fragment thereof, and an application of the pharmaceutical composition as an antineoplastic drug. Particularly, provided is an application of a humanized LAG-3 antibody in preparation of drugs for treatment of diseases involving immune cells.Type: GrantFiled: June 22, 2017Date of Patent: October 26, 2021Assignees: Jiangsu Hengrui Medicine Co., Ltd., Shanghai Hengrui Pharmaceutical Co., Ltd.Inventors: Zhuoxiao Cao, Yayuan Fu, Qiyue Hu, Weikang Tao, Lianshan Zhang, Piaoyang Sun
-
Patent number: 11155786Abstract: The present invention relates to a modified natural killer (NK) cell and its use in personalised medicine. The modified NK cells of the present invention are non-immunogenic, meaning that they are able to be administered to any recipient subject without being rejected by the host immune system (they are “universal”). In a first embodiment the non-immunogenic NK cells are modified to express CD3 to allow a T-cell Receptor (TcR) to be expressed. In a further embodiment the non-immunogenic NK cells are further modified to express a TcR together with the CD3 co-receptor. Co-expression of CD3 with a specific TcR results in the modified NK cells showing antigen-specific cytotoxicity towards target cells. Universal NK cells can thus be targeted against specific antigens, and may thus be used in personalised medicine, particularly in the field of oncology.Type: GrantFiled: January 22, 2016Date of Patent: October 26, 2021Assignee: Oslo Universitetssykehus HFInventors: Sébastien Wälchli, Else Marit Inderberg Suso, Gustav Gaudernack, Gunnar Kvalheim
-
Patent number: 11007212Abstract: The present invention relates to a microbubble complex comprising a microbubble having an outer shell comprising a mixture of native and denatured albumin encapsulating a perfluorocarbon gas, a therapeutic agent, a bifunctional linker having one end attached to the therapeutic agent and the other attached to a ligand and wherein the ligand is bound to the other shell of the microbubble through hydrophobic interactions. Also included are methods for delivering the aforementioned microbubble complex to a tissue target.Type: GrantFiled: June 25, 2018Date of Patent: May 18, 2021Assignee: GENERAL ELECTRIC COMPANYInventors: Anup Sood, Lisa Anne Lowery, Praveena Mohan, James Edward Rothman, John Donald Burczak, Hae Won Lim
-
Patent number: 11007271Abstract: Provided herein is a conjugate comprising two residues of structurally and/or mechanistically different anticancer bioactive agents, coupled to one another by a biocleavable linking moiety, as well as methods of treating cancer using the same and pharmaceutical compositions comprising the same.Type: GrantFiled: June 13, 2017Date of Patent: May 18, 2021Assignee: Ariel Scientific Innovations Ltd.Inventors: Gary Gellerman, Yosi Gilad, Helena Tuchinsky
-
Patent number: 10947316Abstract: An immunoconjugate includes an anti-Globo H antibody, or a binding fragment thereof, and a therapeutic agent or a label, having the formula: Ab?(L?D)m, wherein Ab is the anti-Globo H antibody or the binding fragment thereof, L is a linker or a direct bond, D is the therapeutic agent or the label, and m is an integer from 1 to 8. The antibody may be a monoclonal antibody, which may be a humanized antibody. A method for treating a cancer includes administering to a subject in need of such treatment a pharmaceutically effective amount of an immunoconjugate containing an antibody against Globo H, or a binding fragment thereof, and a therapeutic agent covalently conjugated with the antibody.Type: GrantFiled: June 15, 2018Date of Patent: March 16, 2021Assignee: Development Center for BiotechnologyInventors: Chao-Pin Lee, Shih-Hsien Chuang, Chuan-Lung Hsu, Yi-Jen Chen, Yu-Chin Nieh, Win-Yin Wei, Chia-Cheng Wu
-
Patent number: 10920270Abstract: Methods and compositions are provided for improved nucleic acid amplification assays. In some embodiments, the nucleic acid amplification assay is a tagged amplicon primer extension (TAPE) nucleic acid amplification reaction.Type: GrantFiled: March 22, 2019Date of Patent: February 16, 2021Assignee: Bio-Rad Laboratories, Inc.Inventors: Nicholas Heredia, Dianna Maar
-
Patent number: 10918698Abstract: A novel and thermostable lyophilized pharmaceutical composition of Romiplostim (Fcpeptide fusion protein) along with buffer, bulking agent, stabilizer, and surfactant at pH range of 4.0-6.0.Type: GrantFiled: March 24, 2015Date of Patent: February 16, 2021Assignee: INTAS PHARMACEUTICALS LTD.Inventors: Himanshu Gadgil, Chandresh Chhatbar, Vijaykant Pandey
-
Patent number: 10913786Abstract: The present disclosure relates to isolated polypeptides that inhibit Wnt signaling, pharmaceutical compositions comprising the isolated polypeptides, and methods of use thereof. Nucleic acids, cells, and methods of production related to the isolated polypeptides and compositions are also disclosed.Type: GrantFiled: March 21, 2017Date of Patent: February 9, 2021Assignee: Children's Medical Center CorporationInventors: Min Dong, Liang Tao
-
Patent number: 10905717Abstract: The invention relates to treating individuals with cancer by using blood plasma or blood plasma fractions as treatment.Type: GrantFiled: February 12, 2019Date of Patent: February 2, 2021Assignee: Alkahest, Inc.Inventors: Steven P. Braithwaite, S. Sakura Minami, Joseph McCracken
-
Patent number: 10858438Abstract: This invention relates to binding molecules that bind specifically to TNF-related apoptosis-inducing ligand receptor 2 (TRAILR2) and cadherin-17 (CDH17) and their use in medicine, pharmaceutical compositions comprising the same, and methods of using the same as agents for treatment and/or prevention of cancer.Type: GrantFiled: December 21, 2017Date of Patent: December 8, 2020Assignee: Boehringer Ingelheim International GmbHInventors: Klaus-Peter Kuenkele, Timothy Fenn, Juan Manuel Garcia-Martinez, Jason Ho, Christian Koessl, Saurabh Sen, Vladimir Voynov, Andreas Wernitznig
-
Patent number: 10800856Abstract: This invention relates to prostate-specific membrane antigen (PSMA) antibodies and antibody drug conjugates comprising at least one non-naturally-encoded amino acid. Disclosed herein are ?PSMA antibodies with one or more non-naturally encoded amino acids and further disclosed are antibody drug conjugates wherein the ?PSMA antibodies of the invention are conjugated to one or more toxins. Also disclosed herein are non-natural amino acid dolastatin analogs that are further modified post-translationally, methods for effecting such modifications, and methods for purifying such dolastatin analogs. Typically, the modified dolastatin analogs include at least one oxime, carbonyl, dicarbonyl, and/or hydroxylamine group. Further disclosed are methods for using such non-natural amino acid antibody drug conjugates, dolastatin analogs, and modified non-natural amino acid dolastatin analogs, including therapeutic, diagnostic, and other biotechnology uses.Type: GrantFiled: June 7, 2013Date of Patent: October 13, 2020Assignee: Ambrx, Inc.Inventors: Richard S. Barnett, Feng Tian, Anna-Maria A. Hays Putnam, Marco Gymnopoulos, Nick Knudsen, Andrew Beck, Ying Sun
-
Patent number: 10799597Abstract: The present invention relates to methods of cancer therapy using subcutaneous administration of antibody-drug conjugates (ADCs). Preferably, the ADC comprises an antibody that binds to Trop-2, CEACAM5, CEACAM6, CD20, CD22, CD30, CD46, CD74, Her-2, folate receptor, or HLA-DR. More preferably, the drug is SN-38. Subcutaneous administration is at least as effective as intravenous administration of the same ADC. Surprisingly, subcutaneous administration can be used without inducing unmanageable adverse local toxicity at the injection site. Subcutaneous administration is advantageous in requiring less frequent administration, substantially reducing the amount of time required for intravenous administration, and reducing the levels of systemic toxicities observed with intravenous administration.Type: GrantFiled: March 26, 2018Date of Patent: October 13, 2020Assignee: Immunomedics, Inc.Inventor: David M. Goldenberg
-
Patent number: 10759868Abstract: The present invention relates to Chimeric Antigen Receptors (CAR) that are recombinant chimeric proteins able to redirect immune cell specificity and reactivity toward selected membrane antigens, and more particularly in which extracellular ligand binding is a scFV derived from a 5T4 monoclonal antibody, conferring specific immunity against 5T4 positive cells. The engineered immune cells endowed with such CARs are particularly suited for treating lymphomas and leukemia, and for solid tumors such as colon, stomach, and ovarian tumors.Type: GrantFiled: September 3, 2015Date of Patent: September 1, 2020Assignee: CELLECTISInventor: Cècile Schiffer-Mannioui
-
Patent number: 10731221Abstract: The invention relates to classification, diagnosis and treatment of cancers. In one embodiment, the present invention provides methods and kits that classify cancers into various subtypes based on expression patterns of AKT pathway components. In another embodiment, the present invention provides methods and kits that diagnose cancer subtypes by evaluating expression patterns of AKT pathway components. In still another embodiment, the present invention provides methods and kits that treat a cancer subtype by administering an alkylating agent or a PI3K/AKT/mTOR inhibitor to a patient. Cancers suitable with various embodiments of the invention include but are not limited to brain tumors, gliomas and GBM.Type: GrantFiled: August 14, 2015Date of Patent: August 4, 2020Assignee: Dignity HealthInventors: Anna Joy, Burt G. Feuerstein, Ivan Smirnov
-
Patent number: 10689447Abstract: Described herein are Fc variants and methods for the efficient production of antibodies and other multimeric protein complexes (collectively referred to herein as heteromultimeric proteins). Heteromultimeric proteins may be capable of specifically binding to more than one target. The targets may be, for example, different epitopes on a single molecule or located on different molecules. The methods combine efficient, high gene expression level, appropriate assembly, and ease of purification for the heteromultimeric proteins. The invention also provides methods of using these heteromultimeric proteins, and compositions, kits and articles of manufacture comprising these antibodies.Type: GrantFiled: August 2, 2013Date of Patent: June 23, 2020Assignee: Genentech, Inc.Inventors: J. Michael Elliott, Justin Scheer
-
Patent number: 10682400Abstract: The present invention comprises compositions, methods, and devices for enhancing an endogenous immune response against a cancer. Devices and methods provide therapeutic immunity to subjects against cancer.Type: GrantFiled: April 30, 2015Date of Patent: June 16, 2020Assignees: President and Fellows of Harvard College, Dana-Farber Cancer Institute, Inc.Inventors: Omar Abdel-Rahman Ali, David J. Mooney, Glenn Dranoff